Neuren Pharmaceuticals Limited (ASX:NEU)

Australia flag Australia · Delayed Price · Currency is AUD
20.14
+0.50 (2.55%)
Sep 18, 2025, 4:16 PM AEST
2.55%
Market Cap2.54B
Revenue (ttm)218.86M
Net Income (ttm)149.06M
Shares Out126.29M
EPS (ttm)1.15
PE Ratio17.55
Forward PE72.89
Dividendn/a
Ex-Dividend Daten/a
Volume996,599
Average Volume694,144
Open19.72
Previous Close19.64
Day's Range19.65 - 20.55
52-Week Range8.61 - 20.83
Beta1.75
RSI62.84
Earnings DateAug 29, 2025

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 8
Stock Exchange Australian Securities Exchange
Ticker Symbol NEU
Full Company Profile

Financial Performance

In 2024, Neuren Pharmaceuticals's revenue was 216.83 million, a decrease of -6.51% compared to the previous year's 231.94 million. Earnings were 142.04 million, a decrease of -9.57%.

Financial Statements

News

Neuren Pharmaceuticals Ltd (NURPF) (FY 2024) Earnings Call Highlights: Record Financial ...

Neuren Pharmaceuticals Ltd (NURPF) (FY 2024) Earnings Call Highlights: Record Financial Performance and Strategic Growth Plans

7 months ago - GuruFocus

Full Year 2024 Neuren Pharmaceuticals Ltd Earnings Call Transcript

Full Year 2024 Neuren Pharmaceuticals Ltd Earnings Call Transcript

7 months ago - GuruFocus